Server definition

Hash: sha256:2be2e45659289b984826b44dd1e8173317351679a3cb02cc879857647d5adca4
What it is: What a remote MCP server returned when asked what it offers: 3 tools

The blob, as servednamed by its sha256

{
  "instructions": "Prognyx gives source-linked oncology competitive intelligence. Use compare_trials to set up to three registry studies around an asset or target in one indication side by side, search_registry for the wider trial landscape of a target, company, indication or NCT number, and search_briefings for Prognyx analyses of recent oncology events. Every study carries its ClinicalTrials.gov URL; cite it. Only public research terms are accepted: never send confidential programme names or personal data.",
  "tools": [
    {
      "description": "Up to three interventional ClinicalTrials.gov studies matching an asset or target AND an oncology indication, side by side: sponsor, phase, status, declared arms, primary outcomes, last update, registry URL. Active studies first, then later phase; different sponsors where possible. Use a target (e.g. \"KIF18A\", \"B7-H3\") rather than one drug name to see other programmes.",
      "inputSchema": {
        "additionalProperties": false,
        "properties": {
          "asset": {
            "description": "Public asset or target, e.g. \"sotorasib\", \"KRAS G12C\", \"B7-H3\".",
            "maxLength": 80,
            "type": "string"
          },
          "indication": {
            "description": "Oncology indication, e.g. \"colorectal cancer\", \"NSCLC\".",
            "maxLength": 80,
            "type": "string"
          }
        },
        "required": [
          "asset",
          "indication"
        ],
        "type": "object"
      },
      "name": "compare_trials",
      "outputSchema": null
    },
    {
      "description": "Prognyx oncology competitive-intelligence briefings (each claim linked to a primary source) matching a drug, company, target or indication, newest first, with URL, date and summary.",
      "inputSchema": {
        "additionalProperties": false,
        "properties": {
          "limit": {
            "default": 5,
            "description": "Briefings to return.",
            "maximum": 20,
            "minimum": 1,
            "type": "integer"
          },
          "query": {
            "description": "Drug, company, target or indication. Empty returns the latest.",
            "maxLength": 120,
            "type": "string"
          }
        },
        "type": "object"
      },
      "name": "search_briefings",
      "outputSchema": null
    },
    {
      "description": "Live landscape for a target, asset, company, indication or NCT number: total and active study counts, leading sponsors, phase mix, the most recently updated studies with URLs, and related Prognyx briefings. Counts for phases and sponsors come from a recent sample, stated in the result.",
      "inputSchema": {
        "additionalProperties": false,
        "properties": {
          "limit": {
            "default": 10,
            "description": "Studies to return.",
            "maximum": 25,
            "minimum": 1,
            "type": "integer"
          },
          "query": {
            "description": "e.g. \"KRAS G12C\", \"Nuvalent\", \"claudin 18.2 gastric cancer\", \"NCT05132075\".",
            "maxLength": 160,
            "type": "string"
          }
        },
        "required": [
          "query"
        ],
        "type": "object"
      },
      "name": "search_registry",
      "outputSchema": null
    }
  ]
}

Verify it yourself

curl -s https://api.teppi.xyz/v1/evidence/sha256:2be2e45659289b984826b44dd1e8173317351679a3cb02cc879857647d5adca4 | sha256sum